Brief: Vor Bio Doses First Patient In Global Phase 3 Upstream Sjd Registrational Trial Of Telitacicept In Primary Sjögren’S Disease
30/03/2026 14:47
March 30 (Reuters) - Vor Biopharma Inc VOR.O: VOR BIO DOSES FIRST PATIENT IN GLOBAL PHASE 3 UPSTREAM SJD REGISTRATIONAL TRIAL OF TELITACICEPT IN PRIMARY SJÖGREN’S DISEASE Source text: ID:nGNX6wV1sH Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning